CTMT212X2102: Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics of a Combined Oral Contraceptive (Norethindrone plus Ethinyl Estradiol) in Female Patients with Solid Tumors

February 16, 2019
Cancer - Colorectal, Solid Tumors
Principal Investigator: Ding Wang, MD
Gastrointestinal, Gastrointestinal Anus, Rectal, Rectal Colon, Solid tumors, Phase I, Open-Label, Female, Oral Contraceptive, Norethindrone, Ethinyl Estradiol